Italy Just Bought Its Way Into U.S. Rare Disease

The growth story is compelling because LEMS is still massively underdiagnosed, leaving a long runway for expanded treatment.

Catalyst's second act is AGAMREE (vamorolone), a treatment for Duchenne muscular dystrophy that's growing fast: Q1 2026 revenue hit $36.7 million, up nearly 67% year over year. A third drug, FYCOMPA for epilepsy, is in managed decline thanks to generic competition, but the first two products carry the weight.

Angelini paid $31.50 per share in cash, a 21% premium to Catalyst's unaffected stock price and 28% above the 30-day average. For a rare disease franchise with durable IP (patent settlements with Teva extend protection through February 2035), analysts view the price as full but defensible.

The Part Where the Italian Government Shows Up

This is where the deal gets genuinely unusual. Most pharma acquisitions are funded by some mix of corporate cash, debt, and maybe a stock component. Angelini's financing stack reads like a geopolitical strategy document.

CDP Equity, the investment arm of Italy's state-controlled lender, invested approximately €1 billion for a 23.5% stake in Angelini Pharma through a capital increase. This isn't a loan or a subsidy. It's common equity, meaning CDP sits at the bottom of the capital structure and takes the first hit if things go sideways.

On top of that, Blackstone-managed funds committed another €1 billion in preferred equity, which behaves more like quasi-debt with a senior claim on payouts. A syndicate of 14 banks led by BNP Paribas rounded out the financing with a debt package. No financing condition was attached to the merger agreement, so Angelini was on the hook to close regardless of what credit markets did.

The "why" behind CDP's involvement ties back to its mandate: supporting Italian strategic assets and helping domestic companies scale globally. Italy essentially underwrote a family-owned pharma company's transformation into a transatlantic rare disease player. That's a bold use of state capital, and it's almost unprecedented in European pharma M&A.

Why This Is a Bigger Deal Than One Transaction

Look across Europe's pharmaceutical landscape in 2024 and 2025, and you'll find governments doing plenty: approving State aid for biologics manufacturing in Slovenia, funding radioisotope production in the Netherlands, launching the first IPCEI Health initiative worth up to €1 billion across six member states. But those are all about capabilities and supply chains, not about governments taking equity stakes in companies making cross-border acquisitions.

The Angelini-Catalyst deal breaks that mold. It's a state-backed, cross-border pharmaceutical acquisition where the government isn't just regulating or subsidizing; it's co-investing. CDP is now a minority shareholder in a company that owns U.S. rare disease assets. That's a different animal entirely.

Analysts are framing this as a "sponsored national champion" play, and it fits neatly into a broader 2026 trend: capital flooding into CNS and rare disease assets. UCB, Otsuka, and Eli Lilly have all made big neuroscience bets recently. Angelini is joining that wave, just with a government co-pilot.

The Risks Nobody Wants to Talk About

Integration is the obvious one. Angelini has never managed a U.S. commercial operation. Retaining Catalyst's American sales talent under a family-owned European parent won't be automatic. Cross-border pharma integrations have a long history of stumbling over cultural mismatches and regulatory complexity.

Then there's concentration risk. FIRDAPSE alone accounts for roughly 70% of Catalyst's revenue, and all FIRDAPSE sales flow through a single exclusive U.S. distributor. That's a lot of eggs in a very small number of baskets.

And if the combined company underperforms? Remember, CDP Equity's billion euros sits at the bottom of the capital stack, junior to Blackstone's preferred equity. Italian taxpayers, indirectly, are bearing more downside risk than the private capital partners.

The Bottom Line

Angelini just went from a European mid-cap with no American footprint to the owner of a $600-million-plus U.S. rare disease business, and the Italian government helped pay for it. Catalyst shareholders walk away with $31.50 per share in cash. Catalyst itself has been delisted from Nasdaq.

Whether this becomes a case study in smart state-sponsored industrial policy or an expensive lesson in overreach depends entirely on execution. Angelini now has the platform. The hard part, making it work across an ocean, starts today.

The FDA Just Carpet-Bombed 25 Telehealth Companies Over Knockoff Ozempic

The FDA just hit 25 telehealth companies with warning letters for marketing compounded knockoffs of Ozempic and Mounjaro with bogus claims. It's the third enforcement wave in under a year, with over 100 total letters sent, and the real numbers on patient harm are alarming.